$ABOS 8-K SEC Filings

Filed On	Filing
26 Oct 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure NEWTON, Mass., Oct. 26, 2026 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for ...
16 Sep 2026	8-K: Regulation FD Disclosure Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projec...
12 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
16 Jun 2026	8-K: Regulation FD Disclosure; Other Events
03 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
12 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
26 Mar 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
16 Mar 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
12 Jan 2026	8-K: Regulation FD Disclosure
12 Nov 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
10 Nov 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
12 Aug 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Jul 2025	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
05 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
13 May 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
27 Mar 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
12 Nov 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
13 Aug 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
05 Jun 2024	8-K: Submission of Matters to a Vote of Security Holders
14 May 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Comments